Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and oral P2Y12 inhibitor (P2Y12-I) represents the standard of care for patients with acute coronary syndromes (ACS) or with chronic coronary syndromes (CCS) treated with percutaneous coronary intervention (PCI). Cangrelor, the first intravenous P2Y12-I, is deemed to overcome the drawbacks of the oral administration; nevertheless real world data on this new drug are scanty. We sought to investigate routine clinical use of cangrelor in four interventional centers of Italy.
Clinical use of cangrelor: a real world multicenter experience from South Italy Insights from the M.O.Ca. registry / Pepe, Martino; Larosa, Claudio; Cirillo, Plinio; Carulli, Eugenio; Forleo, Cinzia; Nestola, Palma L; Ercolano, Vincenzo; D'Alessandro, Pasquale; Giordano, Arturo; Biondi-Zoccai, Giuseppe; Moscarelli, Marco; Palmiotto, Angela I; Esposito, Giovanni; Favale, Stefano. - In: PANMINERVA MEDICA. - ISSN 1827-1898. - (2021). [10.23736/S0031-0808.21.04437-2]
Clinical use of cangrelor: a real world multicenter experience from South Italy Insights from the M.O.Ca. registry
Cirillo, PlinioWriting – Original Draft Preparation
;Ercolano, VincenzoMembro del Collaboration Group
;Esposito, Giovanni;
2021
Abstract
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and oral P2Y12 inhibitor (P2Y12-I) represents the standard of care for patients with acute coronary syndromes (ACS) or with chronic coronary syndromes (CCS) treated with percutaneous coronary intervention (PCI). Cangrelor, the first intravenous P2Y12-I, is deemed to overcome the drawbacks of the oral administration; nevertheless real world data on this new drug are scanty. We sought to investigate routine clinical use of cangrelor in four interventional centers of Italy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
